Generalized Anxiety Disorder

Clinical picture

• Free-floating worry shifts across health, finances, work, and family; patients describe the content as realistic but the intensity as excessive.
• Somatic complaints dominate the visit: muscle tension, headaches, GI distress, fatigue, and initial insomnia bring most patients to primary care first.
• Reassurance-seeking, over-preparation, list-making, and checking on loved ones function as safety behaviors that keep the worry cycle running.
• Restlessness, irritability, and impaired concentration are frequently misread as ADHD, occupational burnout, or an irritable depressive episode.
• Onset is insidious; patients commonly report having been worriers for as long as they can remember, with no clear index episode to anchor.
• Functional impact accrues through indecision and procrastination rather than dramatic incapacity, which delays help-seeking by a decade on average.

Criteria snapshot

• Excessive anxiety and worry about several domains, present more days than not for at least six months, that the person finds difficult to control.
• Adults need at least three of six associated symptoms: restlessness, fatigability, concentration difficulty, irritability, muscle tension, disturbed sleep.
• Children and adolescents meet the symptom threshold with only one of those six associated features rather than three.
• The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.
• Not attributable to a substance, medication, or medical condition, and not better explained by panic, social anxiety, OCD, or illness anxiety.

Neurobiology

• Deficient prefrontal top-down regulation of an overactive amygdala; ventromedial prefrontal cortex and anterior cingulate show weak inhibitory control on fMRI.
• GABAergic hypofunction at benzodiazepine binding sites, together with serotonergic and noradrenergic dysregulation, underlies both symptoms and drug response.
• Excess glutamatergic tone and alpha-2-delta calcium channel signaling account for pregabalin efficacy in European anxiety trials.
• Heritability approximates 30-40% and is largely shared with major depression and trait neuroticism; no single locus carries a large effect.
• Chronic HPA axis activation and elevated inflammatory markers such as IL-6 and CRP link GAD to hypertension, irritable bowel, and coronary risk.
• Reduced heart rate variability and blunted vagal tone are reproducible autonomic findings that track with cumulative worry duration.

Psychology

• Intolerance of uncertainty is the core cognitive vulnerability; worry is deployed as an illusory problem-solving strategy for unresolvable ambiguity.
• Positive beliefs about worry (it prepares me, it prevents bad outcomes) coexist with negative meta-worry that worry itself is uncontrollable and harmful.
• Worry is verbal-linguistic activity that suppresses somatic arousal, negatively reinforcing avoidance of full emotional processing (contrast avoidance model).
• Anxious or overprotective parenting and low perceived control in childhood predict adult worry; preoccupied insecure attachment is overrepresented.
• Perfectionism and inflated responsibility drive over-preparation, so good outcomes get attributed to worry rather than competence, sustaining the loop.

Differential & comorbidity

• Rule out hyperthyroidism, arrhythmia, pheochromocytoma, and caffeine, stimulant, or bronchodilator effects before anchoring on a primary anxiety diagnosis.
• Distinguish from panic disorder (episodic surges), social anxiety (evaluation-focused), OCD (ego-dystonic intrusions), and illness anxiety (health-specific).
• Comorbidity is the rule: major depression in roughly 60% lifetime, plus other anxiety disorders and alcohol or sedative misuse.
• Suicide risk rises with comorbid depression and with alcohol or benzodiazepine use; screen at every visit rather than assuming low lethality.
• New-onset worry in an older adult warrants cognitive screening, since early dementia and hypoactive delirium can present as agitated worry.

Pharmacologic treatment

• First-line SSRIs are escitalopram 10-20 mg/day or sertraline 50-200 mg/day; start at half dose and expect 4-6 weeks to full anxiolysis.
• SNRIs venlafaxine XR 75-225 mg/day and duloxetine 60-120 mg/day are equally first-line; monitor blood pressure and discontinuation symptoms.
• Buspirone 15-60 mg/day in divided doses is a non-sedating augmentation option with no abuse liability but a two-week onset.
• Benzodiazepines only as a short bridge under 2-4 weeks; tolerance, falls, cognitive dulling, and dependence outweigh any chronic benefit.
• Pregabalin 150-600 mg/day and low-dose quetiapine have trial support but carry sedation, weight gain, and metabolic burden; keep them second-line.

Psychotherapy

• CBT combining worry exposure, cognitive restructuring, and stimulus control over 12-16 sessions carries the strongest evidence base.
• Applied relaxation and progressive muscle relaxation target the tension component and match CBT outcomes in several head-to-head trials.
• Intolerance-of-uncertainty therapy and metacognitive therapy directly target worry beliefs and yield large effect sizes in randomized trials.
• Acceptance and commitment therapy and mindfulness-based stress reduction reduce worry through decentering rather than through content change.
• Therapy plus medication is preferred for severe or comorbid presentations, and therapy alone lowers relapse risk after treatment ends.

Adjunct options

• Track severity with the GAD-7, where a score of 10 or higher signals clinically significant anxiety, plus the Penn State Worry Questionnaire.
• Aerobic exercise three to five times weekly, caffeine held under 250 mg/day, and consistent sleep-wake timing produce measurable worry reduction.
• Sleep restriction and stimulus control for comorbid insomnia often cut daytime worry more efficiently than another round of dose escalation.
• Digital CBT programs and guided self-help are effective for mild-to-moderate GAD and extend access where specialist waitlists are long.
• Plan the taper early: continue effective pharmacotherapy at least 12 months after remission, then discontinue slowly to limit relapse.

Clinical pearls

• Worry that hops topics but never resolves signals GAD, not the individual crisis of the week.
• Ask what worry accomplishes; positive beliefs about worry predict poor CBT response if unaddressed.
• A GAD-7 of 10 or higher warrants active treatment rather than watchful waiting and reassurance.